Femissis (FEMY) is presented as a 'tightly coiled spring' with three bullish catalysts, including a $30M private placement and FDA clearance for its FemBloc device, suggesting a strong buy opportunity despite its current low stock price.
Source Post
3 Bullish Catalysts Hit FEMY in 3 Weeks! | FEMY Stock Analysis
Aug 29, 2026
The podcast discusses Femissis (FEMY), a microcap medical device company, highlighting three recent catalysts that could significantly de-risk the company and open new growth pathways. Despite a heavily discounted stock price, the analysis suggests potential upside due to a recent $30 million private placement, FDA clearance for a modular PMA submission pathway for their FemBloc device, and a third catalyst involving a potential partnership.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
FEMYbuy opened Aug 29, 2026
-50.90%